Uppsala Reports editor
@UMCGlobalSafety
The READUS-PV statement is the first-ever guide for reports of disproportionality analyses that are replicable, reliable, and reproducible.
Disproportionality analyses are a mainstay of pharmacovigilance research, but despite their prevalence are often misinterpreted, misunderstood, and sometimes misguided.
This is why Michele Fusaroli, Daniele Sartori, and their colleagues published the READUS-PV statement, the first-ever guide to reporting disproportionality analyses. Tune in to find out more about these guidelines and how they came to be, the history and overall impact of guidelines in pharmacological research, and what it means to publish "good" pharmacovigilance science.
Subscribe by visiting the Drug Safety Matters website.
Uppsala Reports editor
@UMCGlobalSafety
MUEs are typically used to improve the safety of drugs, however, may they also have a role in measuring the adherence to risk minimisation measures?
06 August 2025
Spontaneous adverse event reports pose significant challenges to pharmacovigilance scientists. How may we turn them into opportunities that benefit our pharmacovigilance systems?
04 June 2025
Online psychedelic forums hold untapped safety data. AI analysis of user narratives could help pharmacovigilance systems detect risks missed by traditional reporting.
13 November 2025